CCR celebrates National Postdoc Appreciation Week

Posted: Sep 27, 2016

National Postdoc Appreciation Week took place Sept. 19-23. Throughout the week, outstanding postdocs and training opportunities were featured on Twitter. We’ve recapped our coverage in this Storify post.

CCR celebrates National Postdoc Appreciation Week

Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine

Posted: Sep 26, 2016

Thomas Uldrick, senior clinician in the HIV and AIDS Malignancy Branch, has launched a new phase 1 trial evaluating the immunotherapy drug Keytruda, which is designed to target cancer cells in HIV-positive cancer patients. Cancer Today reported that many HIV-positive patients with cancer do not get proper treatment for their cancers, and Uldrick hopes the drug will kill both cancer cells and HIV cells.

Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine

Kent Hunter’s circadian gene research highlighted across national news

Posted: Sep 23, 2016

Kent Hunter’s research on breast cancer metastasis and the circadian gene has been covered by Reuters, Fox News and New Scientist. His research suggests that changes to the gene involved in regulating circadian rhythms could influence the metastasis of breast cancer. Hunter is the Deputy Chief of CCR’s Laboratory of Cancer Biology and Genetics.

Kent Hunter’s circadian gene research highlighted across national news

Steven Pavletic discusses new strategies to target GVHD

Posted: Sep 23, 2016

Steven Pavletic, senior clinician in the Experimental Transplantation and Immunology Branch, discussed new strategies for treating graft-versus-host disease with OncLive. He says these new strategies are the result of improved understanding of the disease’s pathophysiology, and the new therapies could lead to less toxic and more effective therapies.  Learn more...

Steven Pavletic discusses new strategies to target GVHD

NCI Cancer Health Disparities Interest Group presents the first NCI Symposium on Cancer Health Disparities

Posted: Sep 21, 2016

The NCI Cancer Health Disparities Interest Group will host the first NCI Symposium on Cancer Health Disparities on October 18th on the NIH campus. Invited speakers will discuss a number of topics including:

  • Racial and Social Disparities
  • Financial Toxicity and Survivorship
  • Etiologic Heterogeneity and Disease Pathogenesis
  • Strategies to Reduce Cancer Disparities

Learn more...

NCI Cancer Health Disparities Interest Group presents the first NCI Symposium on Cancer Health Disparities

NCI-UMD Partnership for Integrative Cancer Research holds first meeting

Posted: Sep 19, 2016

The NCI-UMD Partnership for Integrative Cancer Research kicked off the Fall 2016 semester with a meet and greet Friday, Sept. 16. The partnership “aims to bring together the expertise and resources in the mathematical sciences, physical sciences, and engineering at the University of Maryland College Park, with basic, clinical, and translational research expertise of the National Cancer Institute/Center for Cancer Research to solve the most pressing problems in cancer research.” CCR Deputy Director Carole Parent is one of the co-directors of the partnership.

NCI-UMD Partnership for Integrative Cancer Research holds first meeting

High levels of potassium inside tumors suppress immune activity

Posted: Sep 15, 2016

Nicholas P. Restifo, a senior investigator in CCR’s Surgery Branch and his team have discovered that an abundance of potassium inside tumors dampens immune responses, helping the tumors evade the body’s defenses. In animal experiments, genetically equipping immune cells rid themselves of potassium made them more effective at fighting cancer. The finding, published September 14, 2016, in the journal Nature, suggests a tactic for improving the effectiveness of cancer immunotherapies.  Learn more...

High levels of potassium inside tumors suppress immune activity

Six-year-old Jordan fights thyroid cancer with the help of the Pediatric Oncology Branch

Posted: Sep 15, 2016

Six-year-old Jordan van Tonder is originally from South Africa, but he comes to CCR’s Pediatric Oncology Branch every six months for thyroid cancer treatment. “He’s always excited about something. He is a great kid and makes me smile whenever I see him,” says Dr. John Glod, his physician and the study’s Principal Investigator.  Jordan is participating in a protocol for multiple endocrine neoplasia type 2b (MEN2B), a rare condition through which he developed thyroid cancer. Read more…

Six-year-old Jordan fights thyroid cancer with the help of the Pediatric Oncology Branch

Pages